INVA - NASDAQ

Innoviva, Inc.

Innoviva, Inc.

INVA·NASDAQ

$21.70

+0.88%
HealthcareBiotechnology

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.60B
EPS4.0200
P/E Ratio5.40
Earnings Date08/05/2026

Earnings Call Transcript

INVA • 2017 • Q1

Executives
Eric d’Esparbes - CFO Michael Aguiar - CEO
Analysts
Prakhar Verma - Stifel
Michael Aguiar
Thank you, Eric. In summary, we remain optimistic about our future prospects based upon ongoing gains in prescription volumes and market share for both products and a steadily improvement financial profile as a business. Our primary focus in 2017 remains the optimization of the commercial success and global rollout of BRIO and ANORO. As we believe the both products have significant future commercial potential and the continued optimization of our capital structure, there are many positive things happening here at Innoviva and we remain optimistic about the outlook of the Company. Now, I'd like to the conference facilitator to open the call for questions.
Operator
Thank you, sir. [Operator Instruction] We will have our first question from the line of Stephen Willey of Stifel. Your line is now open.
Transcript from April 27, 2017

Other Transcripts

 

inva Earnings Call Transcripts

INVA
View Financials All Transcripts

Related Guides

Blog Categories

Continue your INVA research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.